Publications by authors named "Scott Wasserman"

Claim this Profile
D
Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab.
Satoshi Honda, Rishi Puri, Todd Anderson, John J P Kastelein, Danielle M Brennan, Scott M Wasserman

JACC Cardiovasc Imaging· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091].
Adam J Nelson, Rishi Puri, Danielle M Brennan, Todd J Anderson, Leslie Cho, Scott M Wasserman

Am J Prev Cardiol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV.
Adam J Nelson, Rishi Puri, Danielle M Brennan, Todd J Anderson, Leslie Cho, Scott M Wasserman

Am J Prev Cardiol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Robert P Giugliano, Terje R Pedersen, Jeffrey L Saver, Peter S Sever, Anthony C Keech, Scott M Wasserman

Stroke· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.
Michael J Koren, Marc S Sabatine, Robert P Giugliano, Gisle Langslet, Stephen D Wiviott, Scott M Wasserman

J Am Coll Cardiol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Lotte C A Stiekema, Erik S G Stroes, Simone L Verweij, Helina Kassahun, Lisa Chen, Scott M Wasserman

Eur Heart J· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
David M Charytan, Marc S Sabatine, Terje R Pedersen, KyungAh Im, Jeong-Gun Park, Scott M Wasserman

J Am Coll Cardiol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
Edward Lee, John P Gibbs, Maurice G Emery, Geoffrey Block, Scott M Wasserman

Clin Pharmacol Drug Dev· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.
Dick C Chan, Gerald F Watts, Blai Coll, Scott M Wasserman, Santica M Marcovina

J Am Heart Assoc· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Scott M Wasserman

Circulation· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
Arman Qamar, Robert P Giugliano, Anthony C Keech, Julia F Kuder, Sabina A Murphy, Scott M Wasserman

JAMA Cardiol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies.
Erik Stroes, Jennifer G Robinson, Frederick J Raal, Robert Dufour, David Sullivan, Scott M Wasserman

Clin Cardiol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Evolocumab on Coronary Plaque Composition.
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, Scott M Wasserman

J Am Coll Cardiol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.
Scott M Wasserman, Marc S Sabatine, Michael J Koren, Robert P Giugliano, Jason C Legg

J Cardiovasc Pharmacol Ther· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging electronic health records for clinical research.
Sudha R Raman, Lesley H Curtis, Robert Temple, Tomas Andersson, Justin Ezekowitz, Scott M Wasserman

Am Heart J· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.
Seth S Martin, Robert P Giugliano, Sabina A Murphy, Scott M Wasserman, Evan A Stein

JAMA Cardiol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.
Sreeneeranj Kasichayanula, Anita Grover, Maurice G Emery, Megan A Gibbs, Ransi Somaratne, Scott M Wasserman

Clin Pharmacokinet· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Gerald F Watts, Dick C Chan, Ransi Somaratne, Scott M Wasserman, Rob Scott

Eur Heart J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
Dick C Chan, Gerald F Watts, Ransi Somaratne, Scott M Wasserman, Rob Scott

Arterioscler Thromb Vasc Biol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.
Mita Kuchimanchi, Anita Grover, Maurice G Emery, Ransi Somaratne, Scott M Wasserman

J Pharmacokinet Pharmacodyn· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.
Ian Graham, Chuck Shear, Pieter De Graeff, Caroline Boulton, Alberico L Catapano, Scott M Wasserman

Eur Heart J Cardiovasc Pharmacother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park, Gaetano M De Ferrari, Zbigniew A Gaciong, Scott M Wasserman

Lancet· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
Thomas J Povsic, Rob Scott, Kenneth W Mahaffey, Robert Blaustein, Jay M Edelberg, Scott M Wasserman

Cardiovasc Drugs Ther· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Scott M Wasserman

N Engl J Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism".
Gerald F Watts, Dick C Chan, Ransi Somaratne, Scott M Wasserman, Marc S Sabatine

Circulation· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis